US FDA Approves Eye Drops That Could Replace Reading Glasses...| MENAFN.COM

Tuesday, 27 September 2022 09:44 GMT

US FDA Approves Eye Drops That Could Replace Reading Glasses - Breezyscroll


(MENAFN- BreezyScroll)

The United States has approved a new type of eye drop, which could fix or improve age-related blurry vision issues. The eye drop could replace reading glasses.

What is Vuity?

The Food and Drug Administration (FDA) has recently approved a new eye drop for public usage. The eye drop, named Vuity, is designed to improve age-related near-vision problems. Moreover, the medicine is most effective in people aged 40 to 55, who struggle with vision-related issues.

The eye drop is made with the formulation of a famous drug known as pilocarpine.

People with blurry vision problems are advised to apply a drop in each eye once a day. Drop is applied to each eye once a day and starts working within 15 minutes of application. The makers say each drop lasts for at least six hours.

Vuity eye drops rapidly adjust the PH level of the tear film and give temporary relief in vision correction. What the drop does is take advantage of the eye's ability to reduce pupil size, improve near-vision, and maintain distance vision.

Is it effective?

The drop has been found to be most effective for those between the ages of 40 and 55.

Results have come from two randomized control trials on 750 subjects, the report said.

During this research, it was observed that Vuity starts working within 15 minutes of the application. With no serious side effects found, subjects felt mild headaches and eye redness.

Vuity eye drop will cost $79 for a 30-day usage.

FDA Viuty

MENAFN15072022005762012635ID1104537647


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.